

## **AGATHA PHARMACEUTICALS**

### **Board Candidate Backgrounds**

#### **Company shares breakdown:**

\$81.44 per share

**Agatha:** 25% voting shares

**Balwani:** 12% voting shares

**Harris et al:** 9% voting shares

**Medici Hospital Group:** 8% voting shares

**Romney Capital:** 6% voting shares

**Weber Health investors:** 3% voting shares

**Other investors:** 37% voting shares

*Christopher Agatha is stepping down from his Board position in a few days. Due to the vacancy, we are soliciting applications for the Board. All candidates must be current shareholders, and will be voted on by the rest of the shareholders for the position.*

#### **Elizabeth Balwani**

Balwani is a candidate for the Board of Directors. As an original co-founder of the company back in 1970 and the current COO, Balwani has overseen much of the business operations over the past 40 years. She is an aggressive, ambitious leader; she is known to interrupt people while they are speaking to more quickly get to the point, and is effective at making deals.

**She is planning on stepping down from her position as COO to transition into the Board role. Her platform as a candidate has a few major points:**

1. She views her direct company experience as an asset
2. She argues that the company should aggressively transition to its new line of biomechanical engineering products, and that she will help the company find partnerships with major medical groups

3. For its existing suite of pharmaceutical drugs, she argues that the company should seek to change its pricing, and pursue higher profit margins particularly before the intellectual property expires

## **Nora Harris**

Harris is a candidate for the Board of Directors. Despite her youth, Harris has had a diverse career: she has been an Agatha Fellow, was a popular stand-up comedian with her own Netflix special, and is now an impact investor.

Harris is rambunctious and regularly challenges norms: for example, she is known for cutting her hair short and wearing a suit, to challenge notions around masculinity and femininity.

### **As an impact investor, Harris' platform is as follows:**

1. She believes the company needs a fresh perspective
2. She thinks the company should be more transparent in its drug pricing, and clearly articulate for the public how prices are set (e.g. cost of manufacturing, total cost of research, profit margins, etc.)
3. She wants to make the company carbon-neutral by 2030.
4. She wants to re-examine the product design for many of the biomechanical products, namely how its data may impact patient privacy

## Psychotherapy Notes, HIPAA-Protected and **Secret**

**Client:** Harold Beech

**Date:** 7/31

*Harold continues to struggle with mild depression, stemming from his marriage and stress from work.*

### **Relationship**

- He feels as though his wife is primarily in the relationship for prestige (both are Fellows, have high-end jobs); she regularly argues with him about his ambitions at work
- He is bisexual (still closeted) and feels that he has never allowed himself to experience that, especially given society's newfound openness
- He struggles to answer why he is married to his wife; he waffles between truly loving her and appreciating the stability the marriage has brought

### **Work**

- While he tries to do the right thing, he often faces challenges at work. For example, the hospital is considering adopting the Picasso robots -- tools that will likely save lives but may also automate his job away. His wife is vocally opposed.
- Medici Hospital Group is also weighing in on new Board changes at Agatha Pharmaceutical; they are asking for his counsel, and he is not sure which candidate to support. He doesn't want to make a bad decision.

As a whole, Beech is amiable, though hesitant. I am applying **cognitive behavioral therapy** in an attempt to make him more of an assertive self-advocate, in both his relationship and his work.